U.S. Stock News

NYSE:GHM
NYSE:GHMMachinery

Graham (GHM) Stock Looks Priced For Plenty Following Its 7x Run

Graham stock has logged a very strong run over the last several years, yet its latest valuation checks suggest the shares are now pricing in a lot of good news rather than standing out as a clear bargain. Over the past 5 years, Graham has delivered a very large total return of about 7x, which sets a high bar for any further upside case. Recent growth momentum and raised expectations for future revenue may support the current share price, but any setback in demand or profitability could...
NYSE:MCK
NYSE:MCKHealthcare

McKesson (MCK) Publishes New Impact Report On Sustainability And Healthcare Delivery

McKesson (NYSE:MCK) released its Fiscal Year 2026 Impact Report, outlining progress on sustainability, healthcare delivery, and stakeholder engagement. The report provides updated details on environmental goals, community support programs, and partnerships with healthcare providers. It offers investors and other stakeholders a consolidated view of how the company is approaching ESG topics alongside its core distribution and services business. McKesson enters this update with its stock at...
NYSE:CAVA
NYSE:CAVAHospitality

CAVA Stock And 2 Consumer Discretionary Names Worth Watching As Inflation Cools

Cooling US inflation data and sharply lower producer and gasoline prices are reshaping expectations for borrowing costs and consumer budgets, while tensions in the Strait of Hormuz keep the energy outlook uncertain. That mix can reward some U.S. Domestic Consumer Discretionary Stocks exposed to these trends and leave others facing tougher decisions on pricing and costs. This article focuses on three stocks from the screener that appear positively exposed to the recent PPI and CPI moves,...
NYSE:SMR
NYSE:SMRElectrical

Nuclear Energy Stocks For AI Power Demand With NuScale Constellation And Oklo

Nuclear energy stocks sit at the crossroads of power security, inflation concerns and shifting interest rate expectations, as investors look for assets tied to essential infrastructure and long term energy demand. With inflation signals mixed across the US, Europe and Asia, and sovereign yields moving on each new data release, some investors are revisiting nuclear as a potential source of more predictable cash flows within the wider energy mix. This Nuclear Energy Stocks screener highlights...
NYSE:ED
NYSE:EDIntegrated Utilities

Con Edison (ED) Adds Tali Farhadian To Its Board As Oversight Comes Into Focus

Consolidated Edison (NYSE:ED) has elected Tali Farhadian to its Board of Directors. Farhadian brings extensive legal and regulatory experience from public service and legal academia. She has been involved with major New York civic institutions, adding local policy insight to the board. The appointment is intended to strengthen governance and oversight at the utility company. Consolidated Edison, the regulated utility behind electricity, gas, and steam service in New York, operates in a...
NYSE:PNR
NYSE:PNRMachinery

Pentair (PNR) Cuts 2026 Outlook As Pool Weakness And CFO Exit Raise Questions

Pentair (NYSE:PNR) sharply reduced its full-year and Q2 2026 earnings guidance, pointing to ongoing channel inventory destocking. The company highlighted intensified weakness in its Pool segment as a key driver of the revised outlook. Pentair announced the departure of its CFO and appointed an interim CFO, marking a sudden leadership change in its finance function. Pentair enters this guidance reset with its stock trading at $75.68 and down 28.2% year to date and 27.0% over the past year...
NasdaqGS:FRME
NasdaqGS:FRMEBanks

First Merchants (FRME) Stock May Still Be A Bargain As It Rose 55%

First Merchants stock has delivered a 54.7% return over the past three years, and the current valuation checks suggest the share price may still sit below an intrinsic value estimate that screens as undervalued. With both the Excess Returns model and the earnings-based multiples pointing in the same direction, the question is how much of that potential is already reflected at around US$43.30. A 54.7% three-year return highlights that investors have already seen solid gains, which raises the...
NYSE:TME
NYSE:TMEEntertainment

Tencent Music (NYSE:TME) Stock Could Be 36% Undervalued On Cash Flow

Tencent Music Entertainment Group stock is trading well below the intrinsic value estimate from a Discounted Cash Flow (DCF) model, yet the share price has already seen a sharp 1 year decline, so investors are weighing up whether this gap reflects opportunity or ongoing concern. The share price is down 57.7% over the past year, which puts recent market sentiment and expectations for Tencent Music Entertainment Group under pressure. Future cash flow growth from its digital music and audio...
NYSE:BOX
NYSE:BOXSoftware

Box (BOX) Launches Workflow Tools And Expands Abroad As DocuSign Comparisons Grow

Box (NYSE: BOX) has introduced new workflow automation tools for its content platform. The company is also expanding its geographic footprint by entering new markets. These product and market moves are being closely compared with offerings from DocuSign. Box enters this phase of product expansion with its shares trading around $30.0 and a mixed recent track record. The stock is up 18.2% over the past 30 days and 4.0% over the past week, while returns over 1 and 3 years have declined 6.5%...
NasdaqCM:QTTB
NasdaqCM:QTTBBiotechs

Can Q32 Bio (QTTB) Justify Its Valuation Following Strong SIGNAL AA Trial Data?

Q32 Bio (QTTB) has completed a $200 million follow on equity offering, shortly after releasing strong 36 week topline data for its bempikibart Phase 2a SIGNAL AA trial in severe alopecia areata. See our latest analysis for Q32 Bio. Q32 Bio’s recent bempikibart data and the follow on offering come after a period of sharp share price moves, with the 7 day share price return of 35.54% and year to date share price return of 436.63% pointing to strong momentum. The 1 year total shareholder return...
NYSE:DY
NYSE:DYConstruction

3 Stocks Estimated To Be Trading Up To 29.8% Below Intrinsic Value

Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 20% increase over the past year with earnings forecasted to grow by 18% annually. In this context of overall growth, identifying stocks that are trading below their intrinsic value can present potential opportunities for investors seeking to capitalize on undervalued assets.
NYSEAM:XTNT
NYSEAM:XTNTMedical Equipment

SemiLEDs And 2 Other Promising Penny Stocks To Watch

Over the last 7 days, the U.S. market has remained flat, though it is up 20% over the past year with earnings forecasted to grow by 18% annually. Investing in penny stocks—often associated with smaller or newer companies—can still open doors to growth opportunities when these stocks are backed by strong financial health. In this context, we will explore several penny stocks that stand out for their financial strength and potential for long-term success.
NasdaqGS:INDB
NasdaqGS:INDBBanks

Should Rising Earnings Expectations and a Fresh Dividend Require Action From Independent Bank (INDB) Investors?

Independent Bank Corp. recently announced it would release its second-quarter 2026 earnings on July 16, with analysts expecting earnings of US$1.77–US$1.78 per share and revenue of about US$257.73–US$258.95 million. These expectations, alongside a fresh US$0.64 per-share dividend declaration and ongoing analyst estimate revisions, are sharpening investor focus on the bank’s near-term performance. We’ll now examine how the upcoming earnings release and stronger earnings expectations may...
NYSE:CTVA
NYSE:CTVAChemicals

China Mengniu Stock And 2 Trade Tariff Winners And Losers To Watch

New U.S. tariffs of 25% on thousands of Brazilian imports are set to reshape how agricultural and industrial goods move around the world, with roughly $15b in trade directly in the crosshairs. For investors, that kind of shock can quickly split stocks into potential winners and potential losers as input costs, export routes, and customer demand all adjust. This article walks through three stocks exposed to the tariff story, showing how one could find support from shifting trade flows while...
NYSE:WFC
NYSE:WFCBanks

Wells Fargo (WFC) Stock Looks To Trade At A Discount To Fair Value

Wells Fargo has more than doubled investors' money over the past five years, yet its current checks suggest the stock still trades at a discount, with both the intrinsic value estimate and earnings multiples pointing to potential undervaluation rather than excess optimism. A 114.5% return over five years suggests Wells Fargo has already rewarded patient shareholders, so any perceived discount now matters more for future risk and reward. Recent earnings strength and higher capital returns can...
NasdaqCM:AGEN
NasdaqCM:AGENBiotechs

Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise

Agenus (AGEN) is back in focus after fresh Phase 1b data on its botensilimab plus balstilimab regimen in refractory microsatellite stable metastatic colorectal cancer, as well as an oversubscribed private placement tied to its planned ROBBIN Phase 3 trial. See our latest analysis for Agenus. Agenus has been highly volatile, with the share price return up 45.1% over the past week and 57.3% year to date, but the 1 year total shareholder return is still down 18.3% and the 5 year total...
NYSE:RDW
NYSE:RDWAerospace & Defense

Redwire (RDW) Lands $21.5 Million In Marine Corps Drone Awards

Redwire (NYSE:RDW) secured US$21.5 million in follow-on awards to supply uncrewed aircraft systems to the U.S. Marine Corps. The contracts cover additional Advanced Stalker Block 30 systems that align with the Marine Corps' ISR modernization plans. The awards extend an existing relationship, reflecting continued use of Redwire's platform in U.S. defense programs. For investors tracking Redwire, this latest contract underscores the company’s role in supplying uncrewed aircraft systems to...
NYSE:MOD
NYSE:MODBuilding

Modine (MOD) Stock May Be Fairly Valued As 2026 Deal Nears

After a very strong run over the past five years, Modine Manufacturing now screens as only fairly valued on a Discounted Cash Flow (DCF) intrinsic value estimate, while traditional market multiples suggest that the stock is on the expensive side. Modine Manufacturing has delivered a very large 5 year return of about 13x, which means recent buyers are stepping into a stock that has already rewarded long term holders significantly. The planned combination of Modine's Performance Technologies...
NYSE:CCL
NYSE:CCLHospitality

Carnival (CCL) Is Making Alaska A Bigger Part Of Its Growth Plan

Carnival Corporation is highlighting its Alaska business as a key long-term growth driver, with a focus on integrated cruise and land experiences. The company is investing in higher-value Alaska packages, including expansion of its Denali lodge facilities. This shift positions Alaska as a central part of Carnival's broader business strategy for future expansion. Carnival (NYSE:CCL) is putting fresh emphasis on Alaska at a time when its stock trades around $26.5, with a mixed return profile...
NasdaqGS:ASML
NasdaqGS:ASMLSemiconductor

ASML (NasdaqGS:ASML) Lands High NA Chip Milestone As Intel Production Begins

ASML Holding (NasdaqGS:ASML) reports strong Q2 2026 results and raises its quarterly and full-year 2026 sales and margin guidance. Intel Foundry uses ASML's High NA EUV tools for production chips, marking the first high-volume output on this new lithography standard. Management cites robust AI-related demand and outlines plans for significant capacity expansion to support customers. ASML Holding sits at the center of advanced chip production, supplying lithography systems that are essential...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals in a US$10b all cash transaction. The deal brings atumelnant, an advanced clinical stage drug candidate for congenital adrenal hyperplasia, into Vertex's pipeline. The acquisition marks a move by Vertex into adrenal disease therapeutics, expanding beyond its traditional focus areas. For investors following Vertex Pharmaceuticals, this deal signals a push beyond the company’s established franchises and into...